PetMed Express (NASDAQ:PETS) Releases Earnings Results

PetMed Express (NASDAQ:PETS) issued its quarterly earnings data on Monday. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02), RTT News reports. PetMed Express had a negative return on equity of 1.00% and a negative net margin of 0.37%.

PetMed Express Price Performance

PetMed Express stock opened at $4.53 on Wednesday. The firm has a 50 day simple moving average of $5.15 and a 200-day simple moving average of $4.32. PetMed Express has a 1-year low of $2.90 and a 1-year high of $6.85.

Insider Activity

In related news, Director Leslie C.G. Campbell acquired 15,000 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The shares were purchased at an average cost of $5.38 per share, for a total transaction of $80,700.00. Following the acquisition, the director now owns 70,000 shares in the company, valued at $376,600. The trade was a 27.27 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 1.10% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of PetMed Express from a “buy” rating to a “hold” rating in a research report on Tuesday.

PetMed Express Company Profile

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.